Reviva Q2 FY26 net loss narrows to $2.4 million; cash climbs to $19.9 million as of June 30, 2026 - RVPH News | RalliesReviva Q2 FY26 net loss narrows to $2.4 million; cash climbs to $19.9 million as of June 30, 2026
R
RVPH• Q2 results and cash position
- Reviva reported a Q2 net loss of USD 2.4 million, narrowing from a USD 6.1 million loss a year earlier.
- Loss per share improved to USD 0.19 from USD 2.40 in the prior-year quarter.
- Cash and cash equivalents rose to USD 19.9 million at June 30 from USD 14.4 million at Dec. 31.
Patent filing and clinical timeline
- Filed a U.S. composition-of-matter patent application for a new brilaroxazine form, aiming to extend exclusivity through 2046.
- Targets FDA feedback on using the new formulation in RECOVER-2 and an NDA in Q4 2026; RECOVER-2 enrollment planned 1H 2027.
